Patients with two or more risk factors have a very high risk of developing cardiovascular disease. It follows that the strategy for the intervention of multiple risk factors is in fact of paramount relevance in detecting patients at high risk of cardiovascular disease requiring therapeutic intervention. Multiple Risk Factors in Cardiovascular Disease: Vascular and Organ Protection also discusses risk factors from the point of view of biochemists and pharmacologists by addressing the mechanisms underlying the onset of hypertension, hyperlipoproteinaemia, hypercoagulability, and the possibility…mehr
Patients with two or more risk factors have a very high risk of developing cardiovascular disease. It follows that the strategy for the intervention of multiple risk factors is in fact of paramount relevance in detecting patients at high risk of cardiovascular disease requiring therapeutic intervention. Multiple Risk Factors in Cardiovascular Disease: Vascular and Organ Protection also discusses risk factors from the point of view of biochemists and pharmacologists by addressing the mechanisms underlying the onset of hypertension, hyperlipoproteinaemia, hypercoagulability, and the possibility of therapeutic intervention. Audience: Biochemists, pharmacologists and clinical pharmacologists, specialists in the field of cardiovascular medicine seeking to keep abreast of current knowledge in the fast moving field of cardiovascular disease.
Preface. I: Multiple Risk Factors in Population. 1. Lipid Risk Factors and the Regression of Atherosclerosis; A. M. Gotto Jr. 2. Multiple Risk Factors: What is Next? M. Higgins, C. Lenfant 3. Multiple Risk Factors in Northern Italy; G. A. Feruglio, D. Vanuzzo, G. Cesana, M. Ferrario on behalf of the MONICA- Friuli and MONICA-Brianza Study Groups. 4. Long-Term Associations between Hemostatic Variables and Ischemic Heart Disease; T. W. Meade. 5. Cardiovascular Gene Therapy: Possibilities and Realities; V. J. Dzau, R. Morishita, G. H. Gibbons. 6. Triglycerides and Coronary Heart Disease: An Update; M. H. Criqui. II: Lipids and Lipoproteins. 7. Factors Controlling Lipoprotein Metabolism; E. Sehayek, S. Eisenberg. 8. Apolipoproteins in the Treatment of Vascular and Nonvascular Disease; C. R. Sirtori. 9. Explorations of Postprandial Lipids in a Case of Homozygous APO B45.2; B. Jacotot, A. Piolot, M. Ayraut-Jarrier, N. Lemort, C. Martin, S. Braschi, F. Yen, B. Bihain. 10. Apolipoprotein E Binding and Hepatic Lipase-Mediated Catabolism Make Alternate Pathways in the Metabolism of Intermediate Lipoprotein Particles: Observation in Patients with Hepatic Lipase Deficiency; A. Yamamoto, Y. Ikeda, Z. Tsutsumi, A. Mori, A. Takagi, M. Tsushima. III: Critical Aspects of Vascular Protection of New Dihydropyridine Calcium Antagonists. 11. New Aspects of the Pharmacology of Dihydropyridine Calcium Antagonists; T. Godfraind, O. Feron, N. Morel, S. Salomone, M. Wibo. 12. Membrane Interaction of Lipophilic Dihydropyridines as New Mechanisms for Vascular Protection; G. Gaviraghi, D. Trist. 13. Mechanisms of Free Radical Oxidations and Vascular Damage: Protective Effect of Dihydropyridines; F. Ursini. 14. Lipophilic Dihydropyridines: New Opportunities for Prevention of Atherosclerosis; R. Paoletti. 15. Clinical Trial Design and Noninvasive Atherosclerosis Endpoints for Studying Lipophilic Dihydropyridines; M. G. Bond, M. Mercuri, R. Arens, F. Gianfrate for the ELSA Collaborative Research Group. IV: N-3 Fatty Acids and Cardiovascular Risk Factors. 16. The Biological Roles of n-e Fatty Acids: Metabolic and Nutritional Aspects; C. Galli. 17. Effect of Supplementation with Moderate Doses of n-3 Fatty Acid Ethyl Esters to Hypertriglyceridemic Patients on Lipid and Hemostatic Variables; E. Tremoli, S. Colli, P. Maderna, S. Eligini, E. Stragliotto, P. Risé, F. Pazzucconi, C. R. Sirtori, C. Galli. 18. Long-Lasting Inhibition of Platelet Aggregation Following a Relatively Short-Course Administration of n-3 Fatty Acid Ethyl Esters; A. M. Cerbone, T. Cusano, E. Tremoli, C. Galli, F. Cirillo, A. Coppola, E. Stragliotto, A. Amoriello, V. Marottoli, G. Vecchione, G. Di Minno. V: Diabetes. 19. Insulin Resistance and Cardiovascular Risk Factors in Noninsulin-Dependent Diabetes Mellitus; K. G. M. M. Alberti. 20. Glucose as a Risk Factor for Atherosclerosis; R. Bucala, A. Cerami. 21. Dyslipidemia in NIDDM: New Insights; M.-R. Taskinen, M. Syvänne, S. Lahdenperä. 22. Diabetes and Cardiovascular Risk: Epidemiological Aspects; S. M. Haffner. 23. Rational Treatment of the `Plurimetabolic Syndrome'; A. Tiengo, A. Avogaro, S. Del Prato. 24. Kidney Protection in Diabetes Mellitus; K. H. Rahn, M. Barenbrock, B. Suwelack, H. Hohage. 25. Association of Serum Uric Acid with Triglyceride Levels in Female Patients with NIDDM; W. Rathmann, H. Hauner, B. Haastert, K. Kirchner, F. A. Gries. 26. Cardiovascular Disease Prevention in the Elderly; G. Crepaldi, E. Manzato. VI: Diabetic Dyslipidemia and Atherosclerosis: Current Clinical Findings and Treatment Strategies. 27. Insulin Resistance and Coronary Heart Disease; G. M. Reaven. 28. Diabetic Dyslipidemia: The Asian Perspective; T.-Y. Tai, C.-J. Change, Y.-T. Lee. 29. Therapeutic Intervention in Diabetic Dyslipidemia; A. M. Gotto Jr. VII: Hypertension. 30. Red Blood Cell Cation Heteroexchange and Cardiovascular Risk; A. Semplicini, G. Ceolotto, M. Felice, A. Gebbin, A. Fontebasso, R. Valle, L. Serena, C. Dal Palù;. 31. Hypertensio
Preface. I: Multiple Risk Factors in Population. 1. Lipid Risk Factors and the Regression of Atherosclerosis; A. M. Gotto Jr. 2. Multiple Risk Factors: What is Next? M. Higgins, C. Lenfant 3. Multiple Risk Factors in Northern Italy; G. A. Feruglio, D. Vanuzzo, G. Cesana, M. Ferrario on behalf of the MONICA- Friuli and MONICA-Brianza Study Groups. 4. Long-Term Associations between Hemostatic Variables and Ischemic Heart Disease; T. W. Meade. 5. Cardiovascular Gene Therapy: Possibilities and Realities; V. J. Dzau, R. Morishita, G. H. Gibbons. 6. Triglycerides and Coronary Heart Disease: An Update; M. H. Criqui. II: Lipids and Lipoproteins. 7. Factors Controlling Lipoprotein Metabolism; E. Sehayek, S. Eisenberg. 8. Apolipoproteins in the Treatment of Vascular and Nonvascular Disease; C. R. Sirtori. 9. Explorations of Postprandial Lipids in a Case of Homozygous APO B45.2; B. Jacotot, A. Piolot, M. Ayraut-Jarrier, N. Lemort, C. Martin, S. Braschi, F. Yen, B. Bihain. 10. Apolipoprotein E Binding and Hepatic Lipase-Mediated Catabolism Make Alternate Pathways in the Metabolism of Intermediate Lipoprotein Particles: Observation in Patients with Hepatic Lipase Deficiency; A. Yamamoto, Y. Ikeda, Z. Tsutsumi, A. Mori, A. Takagi, M. Tsushima. III: Critical Aspects of Vascular Protection of New Dihydropyridine Calcium Antagonists. 11. New Aspects of the Pharmacology of Dihydropyridine Calcium Antagonists; T. Godfraind, O. Feron, N. Morel, S. Salomone, M. Wibo. 12. Membrane Interaction of Lipophilic Dihydropyridines as New Mechanisms for Vascular Protection; G. Gaviraghi, D. Trist. 13. Mechanisms of Free Radical Oxidations and Vascular Damage: Protective Effect of Dihydropyridines; F. Ursini. 14. Lipophilic Dihydropyridines: New Opportunities for Prevention of Atherosclerosis; R. Paoletti. 15. Clinical Trial Design and Noninvasive Atherosclerosis Endpoints for Studying Lipophilic Dihydropyridines; M. G. Bond, M. Mercuri, R. Arens, F. Gianfrate for the ELSA Collaborative Research Group. IV: N-3 Fatty Acids and Cardiovascular Risk Factors. 16. The Biological Roles of n-e Fatty Acids: Metabolic and Nutritional Aspects; C. Galli. 17. Effect of Supplementation with Moderate Doses of n-3 Fatty Acid Ethyl Esters to Hypertriglyceridemic Patients on Lipid and Hemostatic Variables; E. Tremoli, S. Colli, P. Maderna, S. Eligini, E. Stragliotto, P. Risé, F. Pazzucconi, C. R. Sirtori, C. Galli. 18. Long-Lasting Inhibition of Platelet Aggregation Following a Relatively Short-Course Administration of n-3 Fatty Acid Ethyl Esters; A. M. Cerbone, T. Cusano, E. Tremoli, C. Galli, F. Cirillo, A. Coppola, E. Stragliotto, A. Amoriello, V. Marottoli, G. Vecchione, G. Di Minno. V: Diabetes. 19. Insulin Resistance and Cardiovascular Risk Factors in Noninsulin-Dependent Diabetes Mellitus; K. G. M. M. Alberti. 20. Glucose as a Risk Factor for Atherosclerosis; R. Bucala, A. Cerami. 21. Dyslipidemia in NIDDM: New Insights; M.-R. Taskinen, M. Syvänne, S. Lahdenperä. 22. Diabetes and Cardiovascular Risk: Epidemiological Aspects; S. M. Haffner. 23. Rational Treatment of the `Plurimetabolic Syndrome'; A. Tiengo, A. Avogaro, S. Del Prato. 24. Kidney Protection in Diabetes Mellitus; K. H. Rahn, M. Barenbrock, B. Suwelack, H. Hohage. 25. Association of Serum Uric Acid with Triglyceride Levels in Female Patients with NIDDM; W. Rathmann, H. Hauner, B. Haastert, K. Kirchner, F. A. Gries. 26. Cardiovascular Disease Prevention in the Elderly; G. Crepaldi, E. Manzato. VI: Diabetic Dyslipidemia and Atherosclerosis: Current Clinical Findings and Treatment Strategies. 27. Insulin Resistance and Coronary Heart Disease; G. M. Reaven. 28. Diabetic Dyslipidemia: The Asian Perspective; T.-Y. Tai, C.-J. Change, Y.-T. Lee. 29. Therapeutic Intervention in Diabetic Dyslipidemia; A. M. Gotto Jr. VII: Hypertension. 30. Red Blood Cell Cation Heteroexchange and Cardiovascular Risk; A. Semplicini, G. Ceolotto, M. Felice, A. Gebbin, A. Fontebasso, R. Valle, L. Serena, C. Dal Palù;. 31. Hypertensio
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
